Medicarecard.com MedicareCard Replacement Panel endorses active monitoring and delay of treatment for low-risk prostate cancer

Panel endorses active monitoring and delay of treatment for low-risk prostate cancer

An independent panel convened this week by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression.